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Abstract
Purpose: Bevacizumab is a VEGF-speciﬁc angiogenesis
inhibitor indicated as an adjunct to chemotherapy for the
treatment of multiple cancers. Hypertension is commonly
observed during bevacizumab treatment, and high-grade tox-
icity can limit therapy or lead to cardiovascular complications.
The factors that contribute to interindividual variability in
blood pressure rise during bevacizumab treatment are notwell
understood.
Experimental Design: To identify genomic regions associ-
ated with bevacizumab-induced hypertension risk, sequenc-
ing of candidate genes and ﬂanking regulatory regions was
performed on 61 patients treated with bevacizumab (19 cases
developed early-onset grade 3 hypertension and 42 controls
had no reported hypertension in the ﬁrst six cycles of treat-
ment). SNP-based tests for common variant associations and
gene-based tests for rare variant associations were performed
in 174 candidate genes.
Results: Four common variants in independent linkage
disequilibrium blocks between SLC29A1 andHSP90AB1were
among the top associations. Validation in larger bevacizumab-
treated cohorts supported associationbetween rs9381299with
early grade 3þ hypertension (P ¼ 0.01; OR, 2.4) and systolic
bloodpressure>180mmHg(P¼0.02;OR, 2.1). rs834576was
associated with early grade 3þ hypertension in CALGB 40502
(P ¼ 0.03; OR, 2.9). These SNP regions are enriched for
regulatory elements that may potentially increase gene expres-
sion. In vitro overexpression of SLC29A1 in human endothelial
cells disrupted adenosine signaling and reduced nitric oxide
levels that were further lowered upon bevacizumab exposure.
Conclusions: The genomic region between SLC29A1 and
HSP90AB1 and its role in regulating adenosine signaling are
key targets for further investigation into the pathogenesis of
bevacizumab-induced hypertension. Clin Cancer Res; 24(19);
4734–44. 2018 AACR.
Introduction
Bevacizumab is a recombinant humanized mAb that targets
human VEGF, preventing its binding to VEGFR2; its modes of
action are thought to include the inhibition of angiogenesis (1) as
well as enhanced antigen presentation. Bevacizumab has been
approved by the FDA for the treatment of metastatic colorectal
cancer, advanced nonsquamous non–small cell lung cancer,
metastatic renal cell carcinoma, recurrent glioblastoma, advanced
cervical cancer, and platinum-resistant ovarian cancer (2).
The development of hypertension is frequently observed dur-
ing treatment with bevacizumab. Hypertension of all grades has
been observed in up to 36% of patients treated with bevacizumab
1Department of Bioengineering and Therapeutic Sciences, University of Cali-
fornia San Francisco, San Francisco, California. 2Alliance Statistics and Data
Center, Duke University, Durham, North Carolina. 3Department of Medicine,
Indiana University School of Medicine, Indianapolis, Indiana. 4Department of
Medicine, University of Chicago Comprehensive Cancer, Chicago, Illinois. 5Lab-
oratory for Genotyping Development, RIKEN Center for Integrative Medical
Sciences, Yokohama, Kanagawa, Japan. 6Yale Cancer Center, Yale University
School of Medicine, New Haven, Connecticut. 7Norris Comprehensive Cancer
Center, University of Southern California, Los Angeles, California. 8Southeast
Clinical Oncology Research Consortium, Winston-Salem, North Carolina.
9Department of Medicine, University of California San Francisco, San Francisco,
California. 10Department of Medical Oncology, Kimmel Cancer Center, Thomas
Jefferson University, Philadelphia, Pennsylvania. 11DeBartolo Family Personal-
ized Medicine Institute, Mofﬁtt Cancer Center, Tampa, Florida. 12Center for
Pharmacogenomics and Individualized Therapy, University of North Carolina
at Chapel Hill, Chapel Hill, North Carolina. 13Department of Biostatistics and
Bioinformatics, Duke University School of Medicine, Durham, North Carolina.
Note: Supplementary data for this article are available at Clinical Cancer
Research Online (http://clincancerres.aacrjournals.org/).
ClinicalTrials.gov Identiﬁers: NCT00265850 (CALGB 80405); NCT00110214
(CALGB 90401); NCT00785291 (CALGB 40502); NCT00433511 (ECOG-5103).
Corresponding Author: Deanna L. Kroetz, Department of Bioengineering and
Therapeutic Sciences, University of California San Francisco, 1550 4th Street
RH584E, San Francisco, CA 94158-2911. Phone: 415-476-1159; Fax: 415-514-4361;
E-mail: deanna.kroetz@ucsf.edu
doi: 10.1158/1078-0432.CCR-17-1523
2018 American Association for Cancer Research.
Clinical
Cancer
Research
Clin Cancer Res; 24(19) October 1, 20184734
on July 12, 2019. © 2018 American Association for Cancer Research. clincancerres.aacrjournals.org Downloaded from 
Published OnlineFirst June 5, 2018; DOI: 10.1158/1078-0432.CCR-17-1523 
(3), with grade 3–4 hypertension reported in 1.8% to 22% of
treated patients (4). Generally, the blood pressure increase can be
controlledwith standard antihypertensivemedications.However,
unmanaged hypertension may lead to serious cardiovascular
complications and can occasionally be life-threatening. In the
setting of severe hypertension, bevacizumab is either held tem-
porarily or discontinued, thereby limiting therapy that may
otherwise be beneﬁcial. There are currently no validated bio-
markers to predict bevacizumab toxicity, and the factors that
contribute to interindividual variability in blood pressure rise
during bevacizumab treatment are not well understood.
Prior studies have evaluated and identiﬁed associations
between hypertension incidence during bevacizumab treatment
and common SNPs in candidate genes encoding VEGF (5–9) and
VEGFR2 (10); however, the directions of effect for several of these
ﬁndings are discordant. More recent studies utilizing expanded
candidate gene and genome-wide strategies have identiﬁed risk
variants in SV2C (11) and FIP200 (12) andmodest associations in
EGLN3, EGF, and WNK1 (13). Given the heritable but complex
nature of primary hypertension, the genetic architecture under-
lying bevacizumab-induced hypertension is also likely to be
polygenic. Additional examination of genetic variation in non-
VEGF pathways and of rare variants with potentially large phe-
notypic effects may identify novel mechanisms contributing to
bevacizumab-induced hypertension.
In the current study, candidate genes were sequenced in bev-
acizumab-treated subjects with the objective of identifying genes
harboring multiple variants associated with severe, early-onset
bevacizumab-induced hypertension. Functional studies in
human endothelial cells provide evidence for the potential
involvement of the most signiﬁcant genomic region in this
dose-limiting toxicity.
Materials and Methods
Patient population
The patient cohort for this study was selected from the bev-
acizumab arm of Cancer and Leukemia Group B (CALGB) 80405,
a phase III trial conducted to determine whether the addition of
cetuximab to FOLFIRI or FOLFOX chemotherapy prolongs sur-
vival compared with FOLFIRI or FOLFOX with bevacizumab in
patients with untreated advanced or metastatic colorectal cancer
who have KRAS wild-type tumors. This trial has been described
previously in detail (14). CALGB is now part of the Alliance for
Clinical Trials in Oncology. A total of 899 patients accrued into
the bevacizumab arm and received 5 mg/kg bevacizumab every 2
weeks followed by FOLFOX or FOLFIRI every 2 weeks; treatment
was continued until disease progression, unacceptable toxicity, or
surgery with curative intent. DNA was available from 581 bev-
acizumab-treated patients who were also enrolled in a pharma-
cogenetic companion study (CALGB 60501) embedded within
CALGB 80405. The protocol was approved by the National
Cancer Institute Adult Central IRB and by local Institutional
Review Boards. All participants provided written informed con-
sent for pharmacogenetic sample procurement and analysis. All
studies were conducted in accordance with guidelines outlined in
the Declaration of Helsinki.
Phenotype
Eligibility criteria required that patients with preexisting
hypertension must be well controlled (blood pressure < 160/90
mmHg)on a regimenof antihypertensive therapy. Bloodpressure
was measured prior to randomization, at day 1 of each 8-week
treatment cycle, and every 2 weeks during treatment. Serious
adverse events, including hypertension, were reported during
each cycle. The severity of hypertension was assessed on a scale
of 1 to 5 according to the NCI Common Terminology Criteria for
Adverse Events version 3.
Cases and controls were selected using an extreme phenotype
design to compare severe, early-onset hypertension patients to
those with no reported hypertension (Fig. 1). Cases were deﬁned
as having at least one grade 3 or higher hypertension event during
the ﬁrst three treatment cycles. Forty-eight cases were conﬁrmed
by extensive chart reviews, with 25 having consent and available
DNA. Controls were deﬁned as having no reported hypertension
during the ﬁrst six treatment cycles while completing aminimum
of four uninterrupted cycles with no gaps in adverse event form
coverage; a cutoff of six cycles was chosen to limit the number of
subjects who develop bevacizumab-induced hypertension only
after longer treatment. After identifying 299 potential controls, 53
remained after exclusion for one ormore criteria (Fig. 1). Forty-six
controls who had both pharmacogenetic consent and available
DNA were sequenced.
Sequencing
Genomic DNA extracted from blood samples was provided by
the Alliance Pathology Coordinating Ofﬁce, and sequencing was
performed at the UCSF Genomics Core Facility. Probes were
designed to target the whole exome and intronic, UTR, and 50 kb
regions upstream and downstream of selected candidate genes
(Supplementary Table S1) for a total target size of 85 Mb (64 Mb
standard exomeþ 21Mb custom regions). Candidate genes were
selected based on their documented role in VEGF signaling,
endothelial cell biology, nitric oxide signaling, or hypertension,
as deﬁned by assignment to a curated gene set or pathway inGene
Ontology Consortium (GO, http://www.geneontology.org/),
Kyoto Encyclopedia of Genes and Genomes (http://www.
genome.jp/kegg/), or BioCarta (https://cgap.nci.nih.gov/Pathways/
BioCarta_Pathways). GO annotations were required to be
Translational Relevance
Bevacizumab use in the treatment of cancer can lead to the
development of hypertension in some patients. High-grade
hypertension can lead to cardiovascular complications and
requires delay or discontinuation of therapy. Biomarkers for
the prediction of bevacizumab-induced hypertension could
inform personalized treatment decisions and minimize the
number of patients experiencing this dose-limiting toxicity. A
sequencing analysis of candidate genes identiﬁed a putative
regulatory genomic region between SLC29A1 and HSP90AB1
containing several variants associated with hypertension in
bevacizumab-treated patients with colorectal cancer with
extreme toxicity phenotypes. Functional experiments in
human endothelial cells further suggest that the expression
of SLC29A1 determines in part the cellular response to inhi-
bition of VEGF signaling. The proposed association of novel
genes with bevacizumab-induced hypertension may lead to
improved prediction and management of this toxicity in
patients at elevated hypertension risk.
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supported by experimental evidence, computational evidence,
author statements, or curator statements. The gene sets and path-
ways that were examined for candidate gene selection are listed in
Supplementary Table S2. Additional sequencing and quality
control methods are described in the Supplementary Methods.
SNP-based association testing
Variants were ﬁltered for MAF  0.10 in the study cohort
(threshold chosen based on limited sample size) and LD-pruned
at r2 > 0.8 before testing each variant independently for case–
control association using logistic regression under an additive
genetic model. Tests were adjusted for sex, age, body mass index
(BMI)  25, preexisting hypertension, and preexisting diabetes,
based on published data describing clinical predictors of the
toxicity (15). Associations with Bonferroni-adjusted P values
<0.05 were considered statistically signiﬁcant; unadjusted
P values are reported. Top SNPswere analyzed by in silicomethods
described in the Supplementary Methods.
Gene-based association testing
Association testing was conducted at the gene level to evaluate
combined effects from multiple rare and low frequency variants
(MAF < 0.03) in each gene. Only genes containing more than one
observed rare variant allele were tested. SKAT-O (16), which
combines the sequence kernel association test (SKAT) and a
standard burden test into a single framework and adaptively
selects the best linear combination of test statistics, was used to
test each gene for case-control association. All tests were adjusted
for sex, age, BMI 25, preexisting hypertension, and preexisting
diabetes. Associations with Bonferroni-adjusted P values < 0.05
were considered statistically signiﬁcant; unadjusted P values are
reported.
Replication analysis of top SNP associations
Top SNP associations were tested for replication in two larger,
independent cohorts of patients treated with bevacizumab from
clinical trials CALGB 40502 (17) and CALGB 90401 (18). Asso-
ciations with systolic blood pressure (SBP) >180 mm Hg for
available SNPs were also looked up in the GWAS results of a
third independent cohort in the ECOG-5103 trial (Supplemen-
tary Table S5; ref. 11).
rs3734704 and rs6902226 (proxy for rs6929249 at a physical
distance of 346bp and r2¼ 0.98 in 1000GEUR)were individually
genotyped in both CALGB populations. rs9381299 genotypes
were extracted fromexistingGWASdata. rs6929249and rs834576
genotypes in CALGB 40502 were imputed using genome-wide
genotyping data and sequencing data from the 1000 Genomes
Project (Michigan Imputation Server). SNPs were tested for asso-
ciation with early grade 3þ hypertension using logistic regression
under an additive genetic model. Tests were adjusted for the same
covariates as in the discovery study, where available. Early hyper-
tensionwas deﬁned as hypertension occurring within the number
of treatment cycles equaling the same total exposure of bevaci-
zumab (60 mg/kg) in the ﬁrst three cycles of CALGB 80405.
Associations with Bonferroni-adjusted P values < 0.05 were con-
sidered statistically signiﬁcant; unadjusted P values are reported.
Cell culture
Human umbilical vein endothelial cells (HUVEC; C0035C;
Thermo Fisher Scientiﬁc) were Mycoplasma free upon purchase
Figure 1.
Subject selection from bevacizumab-induced hypertension extreme phenotypes in CALGB 80405. AE, adverse event; BV, bevacizumab; HTN, hypertension; PG,
pharmacogenetic; QC, quality control; tx, treatment.
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and maintained in endothelial cell growth medium-2 (EGM-2;
Lonza) at 37C with 5% CO2. Cells within passages 2–5 were
seeded on 24-well collagen-coated plates for experiments.
Pharmacologic treatment
HUVECs were serum-starved overnight in endothelial basal
medium-2 (EBM-2; Lonza)with 0.5%FBS. Cellswere then treated
for one hour at 37Cwith adenosine (Sigma-Aldrich) and human
VEGF165 (50 ng/mL; Sigma-Aldrich). Where indicated, bevaci-
zumab (provided by Genentech) was added at a 10molar ratio
of VEGF during the 1-hour treatment period.
For inhibitor experiments, cells were preincubated for 30
minutes at 37C with nonselective adenosine receptor antagonist
CGS-15943 (1 mmol/L; Tocris Bioscience) or ENT1 inhibitor S-(4-
Nitrobenzyl)-6-thioinosine (NBTI, 1 mmol/L; Sigma-Aldrich).
Inhibitors were added at the same concentrations during the
1-hour treatment period.
Overexpression of SLC29A1 in HUVECs
At approximately 90% conﬂuency, HUVECs were transiently
transfected according to the manufacturer's protocol with 0.75
mL/well Lipofectamine 3000 (Thermo Fisher Scientiﬁc), 1 mL/well
P3000 reagent (Thermo Fisher Scientiﬁc), and 500 ng/well plas-
mid DNA in EGM-2. Cells were transfected with pcDNA3.1(þ)
vector containing human SLC29A1 cDNA (ORF clone ID
OHu16500D; GenScript). HUVECs transfected with empty
pcDNA3.1(þ) vector (Thermo Fisher Scientiﬁc) were used as
negative controls. Cells were incubated at 37C for 20 hours
following transfection, then serum-starved for 4 hours (instead
of overnight as in untransfected cells) prior to pharmacologic
treatment.
To conﬁrm SLC29A1 overexpression, RNA was isolated using
the RNeasy Mini Kit (Qiagen) and reverse transcribed using the
iScript cDNA Synthesis Kit (Bio-Rad), according to the manufac-
turers' protocols. qRT-PCR reactions prepared withMaxima SYBR
Green/ROX qPCRMaster Mix (Thermo Fisher Scientiﬁc) were run
on the 7900HT Fast Real-time PCR System (Applied Biosystems)
at 95C for 10 minutes, followed by 40 cycles at 95C for 15
seconds and 60C for 1 minute. qRT-PCR data were analyzed by
SDS software v2.4 (Applied Biosystems).
Measurement of cyclic AMP and nitric oxide
Intracellular cyclic AMP levels were measured with a Human
cAMP ELISA Kit (ab133051; Abcam) following sample acetyla-
tion. Total nitrate and nitrite levels, as a measure of nitric oxide,
were measured with a colorimetric Nitric Oxide Assay Kit
(ab65328; Abcam).
Statistical analysis
SNP-based association tests in the discovery sequencing
analysis were performed using PLINK/SEQ (http://atgu.mgh.
harvard.edu/plinkseq/). Gene-based SKAT-O analyses, imple-
mented through the SKAT package (https://CRAN.R-project.
org/package¼SKAT), and logistic regression analyses in repli-
cation cohorts were performed using the R statistical environ-
ment (19).
To analyze functional data, linear trends across adenosine
concentration levels were assessed by the Cochran–Armitage
test. Differences between control and treatment groups (CGS-
15943-treated versus vehicle-treated, NBTI-treated versus vehicle-
treated, SLC29A1-transfected versus empty vector-transfected,
bevacizumab-treated versus vehicle-treated) were analyzed using
unpaired t test or three-way ANOVA, as appropriate. Differences
with two-sided P values < 0.05 were considered statistically
signiﬁcant. Statistical analyses and visualization were conducted
by the Kroetz laboratory andAlliance statisticians using R (19), on
a dataset frozen on February 26, 2013.
Sequence data for the discovery cohort are available via the
NCBI dbGaP repository under accession number phs001597.
v1.p1.
Results
Patient characteristics and selection
Seventy-one samples (25 cases and 46 controls) were selected
for sequencing. Twelve cases developed grade 3 hypertension in
the ﬁrst treatment cycle, 10 cases in cycle 2, and three cases in cycle
3. Following quality control procedures, one samplewas excluded
due to sample contamination (detected by high heterozygosity,
low concordancewithGWASdata, anddiscordant gender). A total
of 61 European samples (19 cases and 42 controls) with complete
sequence and phenotype data were retained for analysis. Demo-
graphic and clinical characteristics of the analyzed cohort are
listed in Table 1 and, with the exception of preexisting hyperten-
sion, are similar between cases and controls and reﬂect the larger
study population.
Candidate gene analysis
In a targeted analysis of 174 prespeciﬁed candidate genes
(Supplementary Table S1) for which additional intronic, UTR,
and ﬂanking regions were sequenced, association testing was
performed on 92,886 coding and noncoding variants (Supple-
mentary Fig. S1). Common variants (MAF  0.10, n ¼ 9,356)
were analyzed in SNP-based association tests (Table 2); no
variants reached Bonferroni-corrected statistical signiﬁcance
(P < 5.3  106). Within the 10 strongest associations, four
SNPs were located in the same intergenic region downstream of
SLC29A1 and upstream of HSP90AB1: rs6929249, rs3734704,
rs834576, and rs9381299 (Supplementary Fig. S2). For all four
SNPs, the proportion of early grade 3 hypertension in minor
allele carriers was consistently higher (58%–70%) than in
noncarriers (6%–24%; Fig. 2).
Table 1. Characteristics of extreme phenotype patient subgroups
Cases Controls
CALGB 80405
bevacizumab arm
CALGB 80405
total population
Subjects (N) 19 42 899 2,334
Female (n, %) 9 (47%) 14 (33%) 364 (40%) 976 (42%)
Age, years (median, range) 59 (31–80) 61 (37–82) 59 (22–85) 59 (21–90)
BMI, kg/m2 (median, range) 25.5 (17.7–40.8) 26.9 (18.6–58.4) 26.8 (14.7–70.7) 27.1 (14.5–70.7)
Preexisting diabetes (n, %) 3 (16%) 4 (10%) 139 (15%) 347 (15%)
Preexisting hypertension (n, %)a 14 (74%) 12 (29%) 361 (40%) 932 (40%)
aDifference between cases versus controls: P ¼ 0.002.
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To test the possibility that individual genes harboring multiple
rare and low frequency variants contribute to toxicity risk, 35,472
variants with MAF < 0.03 in the 174 candidate gene regions were
tested using SKAT-O. No gene associations met statistical signif-
icance after Bonferroni correction (P < 2.9 104; Supplementary
Table S6).
In silico functional analysis
The four SNPs between SLC29A1 and HSP90AB1 identiﬁed
in the candidate gene analysis are noncoding, and all proxy
SNPs (r2 > 0.8) are also in noncoding regions. These variants
were examined for overlap with regulatory elements inferred
from functional data generated in HUVECs from the ENCODE
Project (Supplementary Fig. S3). rs6929249 and rs3734704
are located within 1 kb downstream of the 30 end of SLC29A1
in a moderately transcribed region enriched for histone mod-
iﬁcations linked to gene activation (H3K4me1, H3K27ac,
H3K36me3, H3K79me2) and binding of CTCF, which can act
as an insulator. rs834576 is in a region approximately 3.8 kb
downstream of SLC29A1 that is also enriched for H3K4me1,
H3K27ac, and CTCF as well as additional activating histone
modiﬁcations (H3K4me2, H3K4me3, H3K9ac, H2A.Z) and
binding of RNA polymerase II; the variant site also maps to
a CpG island, a feature often associated with promoters.
rs3734704 and rs834576 also overlap with DNase I hypersen-
sitivity peaks representing regions of open chromatin and are in
genomic segments predicted to be strong enhancers. rs6929249
is in a predicted region of transcriptional transition, and
Table 2. SNP-based analysis of common variants in candidate genes
SNP (ref/var)
Case
genotype
countsa
Control
genotype
countsa
Case
MAF
Control
MAF OR (95% CI) Pb
Candidate
genec Function
rs6929249 (A/G) 5/13/1 36/6/0 0.39 0.07 37.8 (5.8–247) 1  104 HSP90AB1 Upstream
rs3734704 (A/C) 2/14/3 31/10/1 0.53 0.14 28.9 (4.2–199) 6 104 HSP90AB1 Upstream
rs834576 (C/A) 12/6/1 37/5/0 0.21 0.06 19.3 (2.9–127) 0.002 HSP90AB1 Upstream
rs59189065 (G/A) 7/11/1 35/7/0 0.34 0.08 9.9 (2.2–44.3) 0.003 PRKCA Intronic
rs2470417 (C/T) 6/12/1 33/9/0 0.37 0.10 12.7 (2.4–67.5) 0.003 CACNA1C Upstream
rs9381299 (T/C) 9/8/2 35/7/0 0.32 0.08 8.8 (2.0–37.8) 0.004 HSP90AB1 Upstream
rs11651806 (C/G) 13/6/0 11/27/4 0.16 0.41 0.1 (0.0–0.5) 0.004 CCL2 Upstream
rs72869749 (C/T) 9/9/1 35/7/0 0.29 0.08 26.1 (2.8–239) 0.004 PDE3B Intronic
rs142385484 (C/T) 12/7/0 38/3/1 0.18 0.06 13.9 (2.3–84.2) 0.004 NOSIP Downstream
rs11739214 (G/C) 10/6/3 33/9/0 0.32 0.10 10.1 (2.1–48.9) 0.004 FLT4 Downstream
Abbreviation: CI, conﬁdence interval.
aGenotype counts: Homozygous reference/heterozygous/homozygous variant.
bUnadjusted P value from logistic regression under an additive geneticmodel and adjusted for sex, age, BMI25, preexisting hypertension, and preexisting diabetes.
cRepresents candidate gene 50 kb ﬂanking region containing the sequenced variant. In some cases, this may not be the nearest gene to the variant.
Figure 2.
Proportion of early grade 3
hypertension in patients treated with
bevacizumab stratiﬁed by top
SLC29A1-HSP90AB1 SNP carrier status.
Variant alleles of each SNP are
associated with higher incidence of
early grade 3 hypertension (HTN) in
analyzed subjects. Fractions represent
the number of HTN cases over the total
number of subjects for each carrier
status.
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rs9381299 in a predicted region of weak transcription. Similar
data from the Roadmap Epigenomics Project for a diversity of
cell lines corroborated the ENCODE predictions for HUVECs
and support a more global role for the regions containing the
rs6929249, rs3734704, and rs834576 variants as enhancers or
promoters. In a search of previously published eQTL analyses,
the risk allele of rs9381299 was found to be associated with
increased SLC29A1 expression in monocytes (P ¼ 3.8  105,
b ¼ 0.18; ref. 20).
Replication analysis of top SNP associations
rs6929249 (or a proxy SNP, rs6902226), rs3734704, rs834576,
and rs9381299 were tested for association with early grade 3þ
hypertension in independent bevacizumab-treated cohorts with-
in CALGB 40502 and CALGB 90401; imputed rs834576 geno-
types were available only in CALGB 40502. Association of
rs9381299 with SBP > 180 mm Hg was also examined in
ECOG-5103 GWAS data, with SBP > 180 being an even more
extreme phenotype than grade 3þ hypertension, which typically
occurs at SBP > 160. Other SNPs were not available for lookup in
ECOG-5103. Descriptions of these studies and clinical character-
istics of the cohorts used in this study are summarized in Sup-
plementary Tables S5 and S7.
rs9381299 signiﬁcantly associated with early grade 3þ hyper-
tension inCALGB40502 (P¼0.01;OR, 2.4) andwith SBP>180 in
ECOG-5103 (P ¼ 0.02; OR, 2.1) with a concordant direction of
effect, but did not associatewith grade 3þhypertension inCALGB
90401 (Table 3). The proportionof hypertensionwas consistently
higher in risk variant carriers for rs9381299: 5% versus 14% in
CALGB 40502 and 7% versus 16% in ECOG-5103 (Supplemen-
tary Fig. S4). rs834576 also associated with early grade 3þ
hypertension in CALGB 40502 (P ¼ 0.03; OR, 2.9); the propor-
tion of rs834576 risk variant carriers with hypertension was 16%,
compared with 6% of those with the homozygous reference
genotype (Supplementary Fig. S4). The associations of rs6929249
and rs3734704 with grade 3þ hypertension were not validated in
either CALGB cohort
Functional characterization of ENT1 inhibition and SLC29A1
overexpression
SLC29A1 encodes ENT1, a member of the equilibrative nucle-
oside transporter family. ENT1 is responsible for regulating cir-
culating levels of adenosine, which increases endothelial nitric
oxide synthase (eNOS)–dependent activity via adenosine recep-
tor signaling (21). eNOS also lies downstream of VEGF signaling,
and activation of eNOS produces NO, a potent vasodilator. To
follow up on our genetic ﬁndings and the eQTL association with
SLC29A1 expression, the functional effects of SLC29A1 expres-
sion on VEGF signaling were evaluated in HUVECs.
Cyclic AMP (cAMP) levels, as a measure of adenosine receptor
signaling, increased as a function of adenosine concentration (P¼
0.0002; Supplementary Fig. S5). Treatment with the nonselective
adenosine receptor antagonist CGS-15943 almost completely
blocked adenosine-stimulated cAMP formation (P ¼ 0.005; Sup-
plementary Fig. S6), demonstrating the selectivity of cAMP as a
measure of adenosine receptor signaling. Levels ofNO,which acts
as a vasodilatory signaling molecule, also increased as a function
of adenosine concentration (P ¼ 3  105; Supplementary
Fig. S5) and decreased by approximately 50% when adenosine
receptor signaling was blocked (P ¼ 0.002; Supplementary Fig.
S6), indicating thatNO is also generated frompathway(s) distinct
from adenosine signaling.
HUVECs treated with the ENT1 inhibitor NBTI showed
increased cAMP levels compared with vehicle-treated cells
(P ¼ 1  1010; Supplementary Fig. S7), indicating an increase
in adenosine receptor signaling. NBTI-treated HUVECs also
showed increased NO levels compared with controls (P ¼ 6
 1013; Fig. 3A). Addition of bevacizumab resulted in signif-
icant decreases in NO levels both in the presence and absence of
NBTI (P ¼ 5  106; Fig. 3A), without an effect on cAMP levels
(Supplementary Fig. S7). These results are consistent with a
speciﬁc effect of bevacizumab on VEGF-mediated NO produc-
tion without affecting adenosine signaling.
HUVECs transfected with SLC29A1 cDNA were conﬁrmed to
have substantially increased SLC29A1 mRNA expression com-
pared with empty vector–transfected control cells (difference of
relative expression: P ¼ 0.0002). SLC29A1-overexpressing
HUVECs, in the presence of adenosine, decreased the generation
of cAMP when compared with empty vector–transfected controls
at all tested adenosine concentrations (P < 2  1016; Supple-
mentary Fig. S8), indicating a decrease in adenosine receptor
signaling when SLC29A1 expression is increased. SLC29A1-over-
expressing HUVECs showed decreased NO levels compared with
empty vector-transfected cells (P <2 1016; Fig. 3B). Addition of
Table 3. Replication analysis of top SLC29A1-HSP90AB1 SNP associations in independent bevacizumab-treated cohorts
Study Phenotype SNP
Case
genotype
countsa
Control
genotype
countsa
Case
MAF
Control
MAF
OR
(95% CI) Pb
CALGB 40502 Early grade 3þ hypertensionc rs6929249d 19/10/0 278/98/10 0.17 0.15 1.1 (0.5–2.2) 0.81
rs3734704 11/17/1 222/134/30 0.33 0.25 1.5 (0.8–2.6) 0.20
rs834576d 23/6/0 355/30/1 0.10 0.04 2.9 (1.0–7.6) 0.03
rs9381299 16/13/0 303/76/7 0.22 0.12 2.4 (1.2–4.9) 0.01
CALGB 90401 Early grade 3þ hypertensionc rs6902226e 8/5/0 214/82/5 0.19 0.15 1.4 (0.4–3.6) 0.57
rs3734704 6/5/2 164/120/17 0.35 0.26 1.6 (0.6–3.8) 0.29
rs9381299 8/5/0 225/73/3 0.19 0.13 1.7 (0.5–4.7) 0.36
ECOG-5103 SBP > 180 mm Hg rs9381299 23/16/0 308/79/4 0.21 0.11 2.1 (1.1–3.7) 0.02
Abbreviation: CI, conﬁdence interval.
aGenotype counts: Homozygous reference/heterozygous/homozygous variant.
bUnadjusted P value from logistic regression under an additive genetic model and adjusted for covariates listed in Supplementary Table S5.
cEarly hypertension is deﬁned as hypertension occurring within the number of treatment cycles equaling the same total exposure of bevacizumab (60mg/kg) in the
ﬁrst three treatment cycles of CALGB 80405.
drs6929249 and rs834576 genotypes were imputed. The imputation accuracy for these two SNPs was excellent: rs6929249: R2 ¼ 0.95; rs834576: R2 ¼ 0.94.
ers6902226 is a proxy for rs6929249 (r2 ¼ 0.98).
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bevacizumab had no effect on cAMP levels (Supplementary Fig.
S8) but reduced NO levels. The inhibitory effect of bevacizumab
on NO levels ranged from an 18% to 44% decrease in empty
vector–transfected cells compared with a 50% to 75% decrease in
SLC29A1-transfected cells, demonstrating a greater reduction in
NO following bevacizumab treatment under conditions of high
SLC29A1 expression (P ¼ 0.02; Fig. 3B).
Discussion
The current study used a sequencing analysis to discover genes
that potentially contribute to bevacizumab-induced hyperten-
sion. Although no SNP- or gene-based associations achieved
genome-wide signiﬁcance, we identiﬁed SNPs with modest asso-
ciations that may have regulatory effects on biological pathways
related to the phenotype.
A targeted analysis examined variants within and ﬂanking
preselected candidate genes. The top 10 variant associations with
bevacizumab-induced hypertension included four SNPs located
in the same genomic region between SLC29A1 and HSP90AB1.
These SNPs are not in strong LD (r2 < 0.6, Supplementary Figs. S2
and S9), suggesting that they could have independent effects on
the toxicity. Genetic variation in SLC29A1 or HSP90AB1 has not
been previously associated with hypertension or other cardiovas-
cular phenotypes. Although the discovery of common variants
was not the original strategy of this sequencing analysis, other
than rs9381299, these SNPs are not tagged on any standard
commercial GWAS or exome arrays, demonstrating the added
potential of examining variants of all allele frequencies identiﬁed
from sequencing data in the setting of prospectively identiﬁed
clinical outcomes.
SLC29A1 encodes ENT1, which regulates adenosine levels.
Increased circulating adenosine levels have been observed in
ENT1 knockout mice (22), and increased extracellular adenosine
concentrations are associated with reduced ENT1 expression in
HUVECs (23). ENT1 also regulates eNOS-dependent NO pro-
duction via adenosine receptor signaling (21). eNOS lies down-
streamof VEGFandhas been implicated inhypertension resulting
from VEGF inhibition (24).
To investigate whether SLC29A1may inﬂuence an endothelial
cell's response to bevacizumab, functional studies were per-
formed to determine a potential role for ENT1 and adenosine in
the regulation of VEGF-dependent NO production. Under con-
ditions of increased extracellular adenosine from pharmacologic
inhibition of ENT1, bevacizumab selectively inhibited a portion
of NO formation without altering cAMP production, suggesting
that the effects of VEGF inhibition are not simply an off-target
effect on adenosine signaling. Consistent with these ﬁndings,
Figure 3.
Effect of ENT1 inhibition and SLC29A1-overexpression on nitric oxide levels in HUVECs. HUVECs were incubated in 50 ng/mL VEGF and adenosine (0.1, 10,
100mmol/L) for one hour.A, Treatmentwith the ENT1 inhibitor NBTI (1mmol/L) increased levels of nitric oxide (NO;P¼6 1013) comparedwith vehicle-treated cells
at all adenosine concentrations. Exposure to bevacizumab (BV; 10molar ratio of VEGF) decreased NO levels (P¼ 5 106). There was no difference in the effect
of BV on NBTI-treated versus vehicle-treated cells. B, Prior to pharmacologic treatment, an expression vector encoding SLC29A1 cDNA was transfected
intoHUVEC. Empty vector (EV)was transfected intoHUVECas anegative control. SLC29A1 overexpressiondecreased the release of nitric oxidewhen comparedwith
EV-transfected HUVECs (P < 2 1016). Exposure to bevacizumab reduced NO levels in both groups and had a greater inhibitory effect in the SLC29A1-transfected
cells (P ¼ 0.02 compared with bevacizumab effect in EV). Points represent means from three or four independent experiments; lines represent group means.
For each study, the effects of either NBTI treatment or SLC29A1 overexpression and the comparison of bevacizumab exposure at each adenosine concentration
were analyzed by three-way ANOVA.
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overexpression of SLC29A1 in HUVECs caused a decrease in
adenosine receptor signaling that is insensitive toVEGF inhibition
whileNOsynthesis from theparallel VEGFpathwayhas enhanced
sensitivity to bevacizumab under these conditions. Although
these observations must be further validated, we hypothesize
that variants causing increased ENT1 expression and activity may
reduce extracellular adenosine levels and cause vasoconstriction
by impairing the endothelium's ability to maintain a necessary
amount of adenosine-stimulated NO production while under
conditions of reduced VEGF signaling. Patients with increased
ENT1 expression would thereby be more sensitive to changes in
eNOS signaling and NO production from VEGF inhibition by
bevacizumab. Similar changes in sensitivity to bevacizumab
treatment could occur following changes in ENT1 expression or
function as a result of epigenetic regulation of SLC29A1 or drug
interactions.
Variation in other nucleoside transport and adenosine signal-
ing pathway genes may have similar effects on the toxicity.
Changes in ENT1 expression have been reported to directly affect
adenosine deaminase and adenosine A2A receptor expression
(25), and decreased SLC29A1 expression and ENT1 transport
activity have been described during preeclampsia (26, 27), a
complication of pregnancy that is characterized by high blood
pressure. Such changes are accompanied by observations of
increased adenosine concentrations, increased adenosine-gener-
ating enzyme activity (26), reduced A2A receptor expression and
enhanced A2B receptor signaling (27, 28), and upregulation of
soluble VEGFR1 (sFlt-1; refs. 29, 30), which binds to VEGF as
bevacizumab does. Although the association of decreased
SLC29A1 expression with hypertension contradicts our hypoth-
esized mechanism, our ﬁndings still support the idea of dysre-
gulated adenosine transport having an effect on blood pressure.
Expression and activity of these proteins and of other nucleoside
transporters should be considered in future studies of bevacizu-
mab-induced hypertension, as multiple aberrations of the aden-
osine signaling pathway could result in amore sensitive response.
Changes in adenosine transport rates, receptor-binding afﬁnities,
or enzyme kinetics modulated by genetic effects or drug interac-
tions should also be considered during functional studies of
bevacizumab treatment.
Although there was more bioinformatic evidence supporting
the association of the identiﬁed SLC29A1-HPS90AB1 SNPs with
SLC29A1 expression and function,HSP90AB1 is also of biological
interest. This gene encodes a constitutively expressed, cytosolic
isoform of Hsp90, a molecular chaperone that facilitates normal
folding, stability, activation, function, and proteolytic turnover of
many key regulators of cell growth and survival, including eNOS
(31). Reduced Hsp90 expression in primary HUVECs has been
observed during preeclampsia (32), and hypertension has pre-
sented as a common adverse event during early clinical trials of
Hsp90 inhibitor treatment (33, 34). Hsp90 binds to eNOS and
enhances its NO-synthesizing activity (35); at least in part, VEGF
itself signals the binding of Hsp90 with eNOS (36, 37). Disrup-
tion of Hsp90 signaling, either by chemical inhibition or muta-
genesis, has been shown to attenuate VEGF-stimulated binding of
Hsp90 to eNOS, NO production, and endothelium-dependent
relaxation of isolated blood vessels (35, 37–39). Thus, variants
reducing the expression or function of Hsp90 may have similar
effects as increased ENT1 function. Speciﬁcally, reduced baseline
eNOS activity and NO production could amplify the effects of
reduced VEGF signaling during bevacizumab treatment and con-
tribute to the observed dysregulation of vascular tone and
increased blood pressure. Future studies should explore this
possibility and the complex interaction between VEGF, Hsp90,
and adenosine signaling.
Based on data fromour in silico analyses, the identiﬁed SNPs are
located in putative regulatory regions in HUVECs. Three of the
four SNPs are in moderately transcribed regions just downstream
of SLC29A1 that are enriched for epigenetic marks, RNA poly-
merase II binding, and other genomic features associated with
transcriptional activity. Together, these data suggest that this
region may be part of an unannotated SLC29A1 splice variant
or contain an enhancer that regulates expression of a nearby gene.
Variants that alter CTCF-binding sites may disrupt insulator
activity and permit promoter–enhancer interactions in this
region. Detailed analysis of the ENCODE data used for our
in silico analyses found an abundance of disease-associated SNPs
in predicted strong enhancers (40), supporting a role for the
regulatory SNPs identiﬁed in these studies in the bevacizumab-
induced hypertension phenotype. The fourth SNP, rs9381299,
was found to be associated with increased SLC29A1 expression in
monocytes but not in other more relevant tissues like the artery.
Functional studies in vascular endothelial cell models are needed
to better assess the SNP effects on both SLC29A1 and HSP90AB1
expression and function.
These identiﬁed SNPs were tested for association in larger,
independent bevacizumab-treated cohorts. The association of
rs9381299 and rs834576 with early grade 3þ hypertension
in CALGB 40502 and rs9381299 with SBP >180 mm Hg in
ECOG-5103 supports the discovery results. Other SNPs were not
validated. Limitedstatisticalpower, differences in eligibility, clinical
trial design, bevacizumab dosing, and adverse event collection, or
demographic and clinical differences between study populations
may explainwhy someassociations failed to replicate. Inparticular,
CALGB90401 did not have preexistinghypertensiondata available
for adjustment of themodels, whichmight contribute to the lack of
replication in this cohort. Examination of all of these SNPs in
additional bevacizumab-treated cohorts is warranted.
A major limitation of this study is sample size. Because of lack
of consent or available DNA and a rigorous phenotypic review,
many potential subjects could not be sequenced. An extreme
phenotype design was utilized to enrich sampling of causal
variants with large effect sizes and to increase statistical power
(41). Such an approach has beenused in cohorts of similar sizes to
identify novel variants associated with complex disease and
pharmacogenetic traits, such as P. aeruginosa infection (42),
warfarin dosing (43), drug-induced long QT interval syndrome
(44), gemcitabine/carboplatin-induced myelosuppression (45),
and clopidogrel response (46). Considering sample size, we
recognize the limitations of the study design and approach these
analyses largely as a discovery study. Replication and sequencing
are needed in additional cohorts to extend these current ﬁndings.
Another challenge of this study lies in the difﬁculty of identi-
fying true drug-induced hypertension. We limited our phenotype
to hypertension that occurred in the ﬁrst three treatment cycles, as
bevacizumab-induced hypertension has been shown to develop
early (15), thus removing later cases of hypertension that aremore
likely to be attributed to other factors. Preexisting hypertension
was signiﬁcantly correlated with on-treatment hypertension (P ¼
0.002; OR, 6.7), with 14 of 19 (74%) cases having preexisting
hypertension compared with 12 of 42 (29%) controls. This
association is possibly confounding, and genetic models were
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adjusted for preexisting hypertension to minimize this effect.
However, this association has been previously shown (47, 48)
and may possibly be informative. Hypertensive patients were
required to be normotensive upon study initiation, and even
while on antihypertensive medications many still developed the
toxicity. This suggests that some patients may be genetically
predisposed to an especially sensitive response to bevacizumab,
such that even pharmacologically controlled hypertension is
further exacerbated upon bevacizumab treatment. Although the
current study had too few subjects to test this hypothesis, a future
study stratifying by the class of antihypertensivemedication could
elucidate amore speciﬁcmechanism of the toxicity. The inclusion
of subjects from ECOG-5103 as a replication cohort provides
some insight regarding the contribution of the identiﬁed SNPs in
baseline hypertension versus bevacizumab-induced hyperten-
sion. The association of rs9381299 with bevacizumab-induced
hypertension was replicated in ECOG-5103, a cohort that exclud-
ed all patients with preexisting hypertension, supporting our
original discovery results with unbalanced preexisting hyperten-
sion status. Post hoc analyses of the 19 cases of bevacizumab-
induced hypertension used in the discovery analysis matched for
preexisting hypertension status with a new control set of 49
subjects receiving at least four cycles of bevacizumab gave a
similar effect size and direction as the original results for the
three SNPs that could be evaluated (data not shown), further
supporting our discoveryﬁndings. Future genomic and functional
studies are needed to more carefully deﬁne the involvement of
SLC29A1 and HSP90AB1 in these phenotypes.
Hypertension also occurs during treatment with other VEGF
pathway inhibitors (15), including aﬂibercept, a soluble decoy
receptor that binds VEGF, and small-molecule VEGF receptor
tyrosine kinase inhibitors (e.g., sunitinib, sorafenib). The frequen-
cy of all-grade hypertension during treatment with these small-
molecule inhibitors ranges from 15% to 67%, with a greater
incidence observed during treatment withmore potent inhibitors
such as axitinib, regorafenib, and cediranib, where incidence of
grade 3–4 hypertension has been reported as high as 43% (49).
Genetic associations with hypertension during sunitinib treat-
ment have also been reported and include SNPs in VEGFA, KDR,
and NOS3 (eNOS; ref. 50). These pharmacogenetic ﬁndings and
the correlation of potency and hypertension incidence suggest
that the hypertension is primarily an on-target effect of VEGF and
eNOS inhibition, as is hypothesized for bevacizumab-induced
hypertension. Therefore, our results may also be extended to the
study and treatment of other VEGF inhibitor toxicities.
A better understanding of the genetic architecture of bevacizu-
mab-induced hypertension will advance the understanding of
how genetic variability inﬂuences the action of angiogenesis
inhibitors and the pathogenesis of drug-induced hypertension.
Furthermore, identifying genetic predictors of this toxicity could
support the development of improved and novel strategies to
predict and treat pharmacologically induced hypertension and
aid in the selection of appropriate treatment for patients with
cancer. The identiﬁcation of subpopulations of patients at risk for
bevacizumab toxicity will support more aggressive monitoring of
blood pressure and prophylactic antihypertensive treatment in
these patients. Because bevacizumab treatment that may other-
wise be beneﬁcial is held or discontinued upon development of
hypertension, it is clinically important to manage complications
to prolong effective therapy. Blood pressure elevation itself has
beenproposed as amarker for VEGF inhibitor efﬁcacy (51); if true,
this groupmaybe at a therapeutic beneﬁt if their hypertension can
be well controlled.
In this study, potential regulatory bevacizumab-induced hyper-
tension risk variants were identiﬁed near genes not previously
associated with this toxicity. This is the ﬁrst study to date using
sequencing to examine bevacizumab-induced hypertension.
Although our association results weremodest, the region between
SLC29A1 and HSP90AB1 as well as other genes in the adenosine
signaling pathway should be prioritized for follow-up in higher-
powered replication studies and in functional studies to deﬁne the
role of these genes in regulation of vasodilation upon bevacizu-
mab exposure.
Disclosure of Potential Conﬂicts of Interest
B.H. O'Neil is a consultant/advisory board member for Amgen and Genen-
tech. H.S. Hochster is a consultant/advisory board member for Bristol-Myers
Squibb and Roche. H.-J. Lenz reports receiving commercial research grants from
and is a consultant/advisory boardmember for Bristol-Myers Squibb, EMD, and
Genentech. M.J. Ratain is a consultant/advisory board member for Genentech.
A. Venook is a consultant/advisory board member for Genentech/Roche.
D. Kroetz reports receiving commercial research grants from and is a consul-
tant/advisory board member for Genentech. No potential conﬂicts of interest
were disclosed by the other authors.
Authors' Contributions
Conception and design:M. Li, P.N. Friedman, M. Kubo, H.S. Rugo, W.K. Kelly,
H.L. McLeod, A.P. Venook, K. Owzar, D.L. Kroetz
Development of methodology: M. Li, M. Kubo, A.P. Venook, K. Owzar
Acquisition of data (provided animals, acquired and managed patients,
provided facilities, etc.): M. Li, B.H. O'Neil, F. Shen, P.N. Friedman,
Y. Momozawa, M. Kubo, D. Niedzwiecki, H.S. Hochster, H.-J. Lenz, H.S. Rugo,
S. Halabi, W.K. Kelly, H.L. McLeod, F. Innocenti
Analysis and interpretation of data (e.g., statistical analysis, biostatistics,
computational analysis): M. Li, F. Mulkey, C. Jiang, F. Shen, Y. Momozawa,
H.S. Hochster, H.-J. Lenz, H.S. Rugo, S. Halabi, H.L. McLeod, K. Owzar,
D.L. Kroetz
Writing, review, and/or revision of the manuscript:M. Li, F. Mulkey, C. Jiang,
B.H. O'Neil, B.P. Schneider, F. Shen, P.N. Friedman, M. Kubo, D. Niedzwiecki,
H.S. Hochster, H.-J. Lenz, J.N. Atkins, H.S. Rugo, S. Halabi, W.K. Kelly,
H.L. McLeod, F. Innocenti, M.J. Ratain, A.P. Venook, K. Owzar, D.L. Kroetz
Administrative, technical, or material support (i.e., reporting or organizing
data, constructing databases): P.N. Friedman, H.S. Hochster, H.-J. Lenz,
M.J. Ratain, A.P. Venook
Study supervision: D.L. Kroetz
Acknowledgments
Research reported in this publication was supported by the NCI of
the NIH under Award Numbers U10CA180821 and U10CA180882 (to
the Alliance for Clinical Trials in Oncology), U10CA041287, U10CA045808,
U10CA047559, U10CA047577, U24CA114725, U10CA138561,
U10CA180836, U10CA180838, UG1CA189858, CA180830 (to H.-J. Lenz),
CA180826 (to H.S. Hochster), CA180797, CA189828, Alliance Clinical Trial
Foundation (to D.L. Kroetz and A.P. Venook), and the Pharmacogenomics
Development Fund to NIH award number P30CA082103 (to D.L. Kroetz).
M. Li was supported in part by NIH grants T32GM007175 and
F31GM113350. The content is solely the responsibility of the authors and
does not necessarily represent the ofﬁcial views of the NIH.
The costs of publication of this articlewere defrayed inpart by the payment of
page charges. This article must therefore be hereby marked advertisement in
accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
Received May 27, 2017; revised September 7, 2017; accepted May 31, 2018;
published ﬁrst June 5, 2018.
Li et al.
Clin Cancer Res; 24(19) October 1, 2018 Clinical Cancer Research4742
on July 12, 2019. © 2018 American Association for Cancer Research. clincancerres.aacrjournals.org Downloaded from 
Published OnlineFirst June 5, 2018; DOI: 10.1158/1078-0432.CCR-17-1523 
References
1. Ferrara N, Hillan KJ, Gerber HP, Novotny W. Discovery and development
of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug
Discov 2004;3:391–400.
2. Ferrara N, Adamis AP. Ten years of anti-vascular endothelial growth factor
therapy. Nat Rev Drug Discov 2016;15:385–403.
3. Zhu X, Wu S, Dahut WL, Parikh CR. Risks of proteinuria and hypertension
with bevacizumab, an antibody against vascular endothelial growth factor:
systematic review and meta-analysis. Am J Kidney Dis 2007;49:186–93.
4. Ranpura V, Pulipati B, Chu D, Zhu X, Wu S. Increased risk of high-grade
hypertension with bevacizumab in cancer patients: a meta-analysis. Am J
Hypertens 2010;23:460–8.
5. Schneider BP, Wang M, Radovich M, Sledge GW, Badve S, Thor A, et al.
Association of vascular endothelial growth factor and vascular endothelial
growth factor receptor-2 genetic polymorphisms with outcome in a trial of
paclitaxel compared with paclitaxel plus bevacizumab in advanced breast
cancer: ECOG 2100. J Clin Oncol 2008;26:4672–8.
6. Etienne-Grimaldi MC, Formento P, Degeorges A, Pierga JY, Delva R, Pivot
X, et al. Prospective analysis of the impact of VEGF-A gene polymorphisms
on the pharmacodynamics of bevacizumab-based therapy in metastatic
breast cancer patients. Br J Clin Pharmacol 2011;71:921–8.
7. Morita S, Uehara K, Nakayama G, Shibata T, Oguri T, Inada-Inoue M, et al.
Association between bevacizumab-related hypertension and vascular
endothelial growth factor (VEGF) gene polymorphisms in Japanese
patients with metastatic colorectal cancer. Cancer Chemother Pharmacol
2013;71:405–11.
8. Sibertin-Blanc C, Mancini J, Fabre A, Lagarde A, Del Grande J, Levy N, et al.
Vascular Endothelial Growth Factor A c.237C>T polymorphism is asso-
ciated with bevacizumab efﬁcacy and related hypertension in metastatic
colorectal cancer. Dig Liver Dis 2015;47:331–7.
9. Gampenrieder SP, Hufnagl C, Brechelmacher S, Huemer F, Hackl H,
Rinnerthaler G, et al. Endothelin-1 genetic polymorphism as predictive
marker for bevacizumab in metastatic breast cancer. Pharmacogenomics J
2017;17:344–50.
10. Jain L, Sissung TM, Danesi R, Kohn EC, Dahut WL, Kummar S, et al.
Hypertension and hand-foot skin reactions related to VEGFR2 genotype
and improved clinical outcome following bevacizumab and sorafenib. J
Exp Clin Cancer Res 2010;29:95.
11. Schneider BP, Li L, Shen F, Miller KD, Radovich M, O'Neill A, et al. Genetic
variant predicts bevacizumab-induced hypertension in ECOG-5103 and
ECOG-2100. Br J Cancer 2014;111:1241–8.
12. Berger MD, Yamauchi S, Cao S, Hanna DL, Sunakawa Y, Schirripa M, et al.
Autophagy-related polymorphisms predict hypertension in patients with
metastatic colorectal cancer treatedwith FOLFIRI and bevacizumab: results
from TRIBE and FIRE-3 trials. Eur J Cancer 2017;77:13–20.
13. Lambrechts D, Moisse M, Delmar P, Miles DW, Leighl N, Escudier B, et al.
Genetic markers of bevacizumab-induced hypertension. Angiogenesis
2014;17:685–94.
14. Venook AP, Niedzwiecki D, Lenz H-J, Innocenti F, Fruth B, Meyerhardt JA,
et al. Effect of ﬁrst-line chemotherapy combined with cetuximab or
bevacizumab on overall survival in patients with KRASwild-type advanced
or metastatic colorectal cancer: a randomized clinical trial. JAMA 2017;
317:2392–401.
15. Maitland ML, Bakris GL, Black HR, Chen HX, Durand JB, Elliott WJ, et al.
Initial assessment, surveillance, and management of blood pressure in
patients receiving vascular endothelial growth factor signaling pathway
inhibitors. J Natl Cancer Inst 2010;102:596–604.
16. Lee S, EmondMJ, Bamshad MJ, Barnes KC, Rieder MJ, Nickerson DA, et al.
Optimal uniﬁed approach for rare-variant association testing with appli-
cation to small-sample case-control whole-exome sequencing studies. Am J
Hum Genet 2012;91:224–37.
17. Rugo HS, Barry WT, Moreno-Aspitia A, Lyss AP, Cirrincione C, Leung E,
et al. Randomized phase III trial of paclitaxel once per week compared with
nanoparticle albumin-bound nab-paclitaxel once per week or ixabepilone
with bevacizumab as ﬁrst-line chemotherapy for locally recurrent or
metastatic breast cancer: CALGB 40502/NCCTG N063H (Alliance). J Clin
Oncol 2015;33:2361–9.
18. Kelly WK, Halabi S, Carducci M, George D, Mahoney JF, Stadler WM, et al.
Randomized, double-blind, placebo-controlled phase III trial comparing
docetaxel and prednisone with or without bevacizumab in men with
metastatic castration-resistant prostate cancer: CALGB 90401. J Clin Oncol
2012;30:1534–40.
19. R Core Team. R: a language and environment for statistical computing.
Vienna, Austria: R Foundation for Statistical Computing; 2013. Available
from: https://www.R-project.org/.
20. Fairfax BP, Makino S, Radhakrishnan J, Plant K, Leslie S, Dilthey A, et al.
Genetics of gene expression in primary immune cells identiﬁes cell
type–speciﬁc master regulators and roles of HLA alleles. Nat Genet
2012;44:502–10.
21. San Martín R, Sobrevia L. Gestational diabetes and the adenosine/L-
arginine/nitric oxide (ALANO) pathway in human umbilical vein endo-
thelium. Placenta 2006;27:1–10.
22. Rose JB, Naydenova Z, Bang A, Ramadan A, Klawitter J, Schram K, et al.
Absence of equilibrative nucleoside transporter 1 in ENT1 knockout mice
leads to altered nucleoside levels following hypoxic challenge. Life Sci
2011;89:621–30.
23. VasquezG, Sanhueza F, Vasquez R, GonzalezM, SanMartín R, Casanello P,
et al. Role of adenosine transport in gestational diabetes-induced L-argi-
nine transport and nitric oxide synthesis in human umbilical vein endo-
thelium. J Physiol 2004;560:111–22.
24. Facemire CS, Nixon AB, Grifﬁths R, Hurwitz H, Coffman TM. Vascular
endothelial growth factor receptor 2 controls blood pressure by regulating
nitric oxide synthase expression. Hypertension 2009;54:652–8.
25. Bone DBJ, Choi DS, Coe IR, Hammond JR. Nucleoside/nucleobase trans-
port and metabolism by microvascular endothelial cells isolated from
ENT1-/- mice. Am J Physiol Heart Circ Physiol 2010;299:H847–56.
26. Salsoso R, Farías M, Gutierrez J, Pardo F, Chiarello DI, Toledo F, et al.
Adenosine and preeclampsia. Mol Aspects Med 2017 Jan 12. [Epub ahead
of print].
27. Escudero C, Casanello P, Sobrevia L. Human equilibrative nucleoside
transporters 1 and 2 may be differentially modulated by A2B adenosine
receptors in placenta microvascular endothelial cells from pre-eclampsia.
Placenta 2008;29:816–25.
28. Acurio J, Troncoso F, Bertoglia P, Salomon C, Aguayo C, Sobrevia L, et al.
Potential role of A2B adenosine receptors on proliferation/migration of
fetal endothelium derived from preeclamptic pregnancies. Biomed Res Int
2014;2014:274507.
29. Powe CE, Levine RJ, Karumanchi SA. Preeclampsia, a disease of the
maternal endothelium: the role of antiangiogenic factors and implications
for later cardiovascular disease. Circulation 2011;123:2856–69.
30. Iriyama T, Sun K, ParchimNF, Li J, Zhao C, Song A, et al. Elevated placental
adenosine signaling contributes to the pathogenesis of preeclampsia.
Circulation 2015;131:730–41.
31. Taipale M, Jarosz DF, Lindquist S. HSP90 at the hub of protein
homeostasis: emerging mechanistic insights. Nat Rev Mol Cell Biol
2010;11:515–28.
32. Gu Y, Lewis DF, Zhang Y, Groome LJ, Wang Y. Increased superoxide
generation and decreased stress protein Hsp90 expression in human
umbilical cord vein endothelial cells (HUVECs) from pregnancies com-
plicated by preeclampsia. Hypertens Pregnancy 2006;25:169–82.
33. Yong K, Cavet J, Johnson P, Morgan G, Williams C, Nakashima D, et al.
Phase I study of KW-2478, a novel Hsp90 inhibitor, in patients with B-cell
malignancies. Br J Cancer 2016;114:7–13.
34. Maddocks K,Hertlein E, Chen TL,Wagner AJ, Ling Y, Flynn J, et al. A phase I
trial of the intravenous Hsp90 inhibitor alvespimycin (17-DMAG) in
patients with relapsed chronic lymphocytic leukemia/small lymphocytic
lymphoma. Leuk Lymphoma 2016;57:2212–5.
35. García-Carde~naG, Fan R, Shah V, Sorrentino R, CirinoG, Papapetropoulos
A, et al. Dynamic activation of endothelial nitric oxide synthase by Hsp90.
Nature 1998;392:821–4.
36. Brouet A, Sonveaux P, Dessy C, Balligand J-L, Feron O. Hsp90 ensures the
transition from the early Ca2þ-dependent to the late phosphorylation-
dependent activation of the endothelial nitric-oxide synthase in vascular
endothelial growth factor-exposed endothelial cells. J Biol Chem 2001;
276:32663–9.
37. Duval M, Le Bœuf F, Huot J, Gratton J-P. Src-mediated phosphorylation of
Hsp90 in response to vascular endothelial growth factor (VEGF) is required
for VEGF receptor-2 signaling to endothelial NO synthase. Mol Biol Cell
2007;18:4659–68.
www.aacrjournals.org Clin Cancer Res; 24(19) October 1, 2018 4743
SLC29A1 Locus and Bevacizumab-Induced Hypertension
on July 12, 2019. © 2018 American Association for Cancer Research. clincancerres.aacrjournals.org Downloaded from 
Published OnlineFirst June 5, 2018; DOI: 10.1158/1078-0432.CCR-17-1523 
38. Papapetropoulos A, García-Carde~na G, Madri JA, Sessa WC. Nitric oxide
production contributes to the angiogenic properties of vascular endo-
thelial growth factor in human endothelial cells. J Clin Invest 1997;
100:3131–9.
39. Miao RQ, Fontana J, Fulton D, Lin MI, Harrison KD, Sessa WC.
Dominant-negative Hsp90 reduces VEGF-stimulated nitric oxide release
and migration in endothelial cells. Arterioscler Thromb Vasc Biol
2008;28:105–11.
40. Ernst J, Kheradpour P,Mikkelsen TS, ShoreshN,Ward LD, Epstein CB, et al.
Mapping and analysis of chromatin state dynamics in nine human cell
types. Nature 2011;473:43–9.
41. Barnett IJ, Lee S, Lin X. Detecting rare variant effects using extreme
phenotype sampling in sequencing association studies. Genet Epidemiol
2013;37:142–51.
42. Emond MJ, Louie T, Emerson J, Zhao W, Mathias RA, Knowles MR, et al.
Exome sequencing of extreme phenotypes identiﬁes DCTN4 as a modiﬁer
of chronic Pseudomonas aeruginosa infection in cystic ﬁbrosis. Nat Genet
2012;44:886–9.
43. Daneshjou R, Gamazon ER, Burkley B, Cavallari LH, Johnson JA,
Klein TE, et al. Genetic variant in folate homeostasis is associated
with lower warfarin dose in African Americans. Blood 2014;124:
2298–305.
44. Weeke P,Mosley JD,HannaD,Delaney JT, Shaffer C,WellsQS, et al. Exome
sequencing implicates an increased burden of rare potassium channel
variants in the risk of drug-induced long QT interval syndrome. J Am Coll
Cardiol 2014;63:1430–7.
45. Green H, Hasmats J, Kupershmidt I, Edsg€ard D, de Petris L, Lewensohn R,
et al. Using whole-exome sequencing to identify genetic markers for
carboplatin and gemcitabine-induced toxicities. Clin Cancer Res 2016;22:
366–73.
46. Scott SA, Collet J-P, Baber U, Yang Y, Peter I, Linderman M, et al. Exome
sequencing of extreme clopidogrel response phenotypes identiﬁes
B4GALT2 as a determinant of on-treatment platelet reactivity. Clin Phar-
macol Ther 2016;100:287–94.
47. Wicki A, Hermann F, Pre^tre V, Winterhalder R, KuengM, vonMoos R, et al.
Pre-existing antihypertensive treatment predicts early increase in blood
pressure during bevacizumab therapy: the prospective AVALUE cohort
study. Oncol Res Treat 2014;37:230–6.
48. Hamnvik OP, Choueiri TK, Turchin A, McKay RR, Goyal L, Davis M,
et al. Clinical risk factors for the development of hypertension in
patients treated with inhibitors of the VEGF signaling pathway. Cancer
2015;121:311–9.
49. Brinda BJ, Viganego F, Vo T, Dolan D, Fradley MG. Anti-VEGF-induced
hypertension: a review of pathophysiology and treatment options. Curr
Treat Options Cardiovasc Med 2016;18:33.
50. Semeniuk-Wojtas´ A, Lubas A, Stec R, Szczylik C, Niemczyk S. Inﬂuence of
tyrosine kinase inhibitors on hypertension and nephrotoxicity in meta-
static renal cell cancer patients. Int J Mol Sci 2016;17:2073.
51. Maitland ML, Moshier K, Imperial J, Kasza KE, Karrison T, Elliott W, et al.
Blood pressure (BP) as a biomarker for sorafenib (S), an inhibitor of the
vascular endothelial growth factor (VEGF) signaling pathway. J ClinOncol
(Meeting Abstracts) 2006;24:2035.
Clin Cancer Res; 24(19) October 1, 2018 Clinical Cancer Research4744
Li et al.
on July 12, 2019. © 2018 American Association for Cancer Research. clincancerres.aacrjournals.org Downloaded from 
Published OnlineFirst June 5, 2018; DOI: 10.1158/1078-0432.CCR-17-1523 
2018;24:4734-4744. Published OnlineFirst June 5, 2018.Clin Cancer Res 
  
Megan Li, Flora Mulkey, Chen Jiang, et al. 
  
Hypertension: CALGB 80405 (Alliance)
 Associated with Risk of Bevacizumab-InducedHSP90AB1
 and SLC29A1Identification of a Genomic Region between 
  
Updated version
  
 10.1158/1078-0432.CCR-17-1523doi:
Access the most recent version of this article at:
  
Material
Supplementary
  
 http://clincancerres.aacrjournals.org/content/suppl/2018/06/05/1078-0432.CCR-17-1523.DC1
Access the most recent supplemental material at:
  
  
  
  
  
Cited articles
  
 http://clincancerres.aacrjournals.org/content/24/19/4734.full#ref-list-1
This article cites 49 articles, 12 of which you can access for free at:
  
  
  
E-mail alerts  related to this article or journal.Sign up to receive free email-alerts
  
Subscriptions
Reprints and 
  
.pubs@aacr.org
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at
  
Permissions
  
Rightslink site. 
Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC)
.http://clincancerres.aacrjournals.org/content/24/19/4734
To request permission to re-use all or part of this article, use this link
on July 12, 2019. © 2018 American Association for Cancer Research. clincancerres.aacrjournals.org Downloaded from 
Published OnlineFirst June 5, 2018; DOI: 10.1158/1078-0432.CCR-17-1523 
